Skip to main content
PLOS One logoLink to PLOS One
. 2022 Jul 7;17(7):e0270966. doi: 10.1371/journal.pone.0270966

Prevalence of and risk factors for depression, anxiety, and stress in non-hospitalized asymptomatic and mild COVID-19 patients in East Java province, Indonesia

Michael Austin Pradipta Lusida 1,2,, Sovia Salamah 3,4,‡,*, Michael Jonatan 1,5, Illona Okvita Wiyogo 1,6, Claudia Herda Asyari 1,7, Nurarifah Destianizar Ali 1, Jose Asmara 1,8, Ria Indah Wahyuningtyas 1,9, Erwin Astha Triyono 1,2, Ni Kadek Ratnadewi 1,10, Abyan Irzaldy 11, Firas Farisi Alkaff 4,12,*
Editor: Peter G van der Velden13
PMCID: PMC9262201  PMID: 35797394

Abstract

Background

Despite abundant data on mental health during the COVID-19 pandemic, 3 important knowledge gaps continue to exist, i.e., 1) studies from low-/middle income countries (LMICs); 2) studies in the later period of the COVID-19 pandemic; and 3) studies on non-hospitalized asymptomatic and mild COVID-19 patients. To address the knowledge gaps, we assessed the prevalence of and the risk factors for mental health symptoms among non-hospitalized asymptomatic and mild COVID-19 patients in one LMIC (Indonesia) during the later period of the pandemic.

Methods

This cross-sectional study was conducted in September 2020 in East Java province, Indonesia. Study population consisted of non-hospitalized asymptomatic and mild COVID-19 patients who were diagnosed based on reverse transcriptase-polymerase chain reaction results from nasopharyngeal swab. Mental health symptoms were evaluated using the Depression Anxiety Stress Scale-21.

Results

From 778 non-hospitalized asymptomatic and mild COVID-19 patients, 608 patients were included in the analysis. Patients’ median age was 35 years old and 61.2% were male. Of these, 22 (3.6%) reported symptoms of depression, 87 (14.3%) reported symptoms of anxiety, and 48 (7.9%) reported symptoms of stress. Multivariate logistic regression analysis showed that females were more likely to report symptoms of stress (adjusted odds ratio (aOR) = 1.98, p-value = 0.028); healthcare workers were more likely to report symptoms of depression and anxiety (aOR = 5.57, p-value = 0.002 and aOR = 2.92, p-value = 0.014, respectively); and those with a recent history of self-quarantine were more likely to report symptoms of depression and stress (aOR 5.18, p = 0.004 and aOR = 1.86, p = 0.047, respectively).

Conclusion

The reported prevalence of mental health symptoms, especially depression, was relatively low among non-hospitalized asymptomatic and mild COVID-19 patients during the later period of the COVID-19 pandemic in East Java province, Indonesia. In addition, several risk factors have been identified.

Introduction

Since 11 March 2020, severe acute respiratory syndrome coronavirus-2 that causes coronavirus disease 2019 (COVID-19) has been classified as a pandemic by the World Health Organization [1]. Currently, this virus has infected more than 500 million people and cause over 6 million deaths worldwide [2]. As human-to-human transmission occurs upon close contact with an infected person via respiratory droplets or aerosols [3], various preventive public health measures such as quarantine, social distancing, curfews, and lockdowns were implemented to prevent the spread of infection [4].

While these measures were deemed effective in limiting progression of the pandemic, they were not without consequences. People had to abruptly change their daily routines, working models, and social interactions. For example, working parents had to also mind their child(ren) while working from home, all meetings had to be switched from offline to online, business and leisure trips had to be cancelled, and physical contact such as handshakes or hugs were even prohibited. Hence, an increase in the prevalence of individuals with mental health symptoms was to be expected [57].

In the beginning of the COVID-19 pandemic, only little attention was paid to the impact of the COVID-19 pandemic on mental health [8]; but now, a great number of studies on this topic have been published. In a recent meta-review of meta-analyses, the prevalence of depression and anxiety during the COVID-19 pandemic was reported to be 26.93% and 27.77%, respectively [9]. These values are strikingly higher compared to pre-pandemic era, where the prevalence was estimated to be 4.4% for depression and 3.6% for anxiety [10]. Additionally, several risk factors that could adversely affect mental health during the COVID-19 pandemic have been identified, such as age, gender, educational background, socioeconomic status, marital status, the presence of children, occupation as healthcare worker (HCW), and a history of self-quarantine [1113]. Nevertheless, despite the growing body of scientific literature on mental health during the COVID-19 pandemic, 3 important knowledge gaps exist.

First, although the COVID-19 pandemic has affected all countries around the globe, its impact on mental health varies across countries, with mental health symptoms being more prevalent in low-/middle-income countries (LMICs) compared to high-income countries [14]. Even so, most of the studies that have evaluated the impact of mental health during the COVID-19 pandemic originated from China, while studies from LMICs are lacking [1517]. Second, the impact of the COVID-19 pandemic on mental health differs across time periods, with mental health symptoms being more severe in the beginning of the pandemic and become significantly milder in the following months [18]. Nonetheless, majority of the studies that evaluated mental health were conducted in the beginning of the pandemic [16, 18, 19], which may overestimate the magnitude of mental health problems during the COVID-19 pandemic. Third, previous studies have shown that adverse mental health symptoms are more prevalent among COVID-19 patients compared to the general population or HCWs [12, 14, 16, 20, 21]. Even so, studies assessing mental health during the COVID-19 pandemic rarely focused on the COVID-19 patients [22]. Among COVID-19 patients, those who are hospitalized are at higher risk of having adverse mental health symptoms compared to those who are not hospitalized [2325]. This is because most of the hospitalized patients are patients with severe COVID-19 symptoms [26], and patients with severe COVID-19 symptoms are more likely to have adverse mental health symptoms than the non-severe one [27, 28]. Nevertheless, majority of COVID-19 patients are asymptomatic or presented with only mild symptoms that do not require hospitalization [24, 25, 2932]. However, data pertaining to the mental health condition of non-hospitalized asymptomatic and mild COVID-19 patients are lacking [33]. In addition, no study has explored the risk factors of adverse mental health symptoms in this group of patients.

Thus, to address the aforementioned knowledge gaps, we conducted a study in Indonesia, one of the LMICs in Southeast Asia, during the later period of the COVID-19 pandemic, with non-hospitalized asymptomatic and mild COVID-19 patients as the study population.

Materials and methods

Study design and study population

This cross-sectional study was conducted between 1 and 30 September 2020 in East Java province, Indonesia. During this period, the number of cases was the highest in the country since the beginning of the pandemic [34]. Among 34 provinces in Indonesia, East Java province was the province with the second highest confirmed cases and the highest mortality rate [35].

The study population consisted of non-hospitalized asymptomatic and mild COVID-19 patients. Respondents were recruited at the Indrapura Emergency Field Hospital, the largest government-owned quarantine facility in East Java province, Indonesia. To be admitted to this quarantine facility, patients had to fulfill the following criteria: 1) Tested positive for COVID-19 on reverse transcriptase-polymerase chain reaction (RT-PCR) test; 2) Asymptomatic or having mild COVID-19 symptoms; and 3) able to take care of themselves.

To avoid the possible effect of facilitated quarantine on mental health, respondents were recruited before they underwent quarantine. When the patients came to the registration desk, those who fulfilled the inclusion criteria were verbally offered to participate in this study by the registrar. If the patients agreed to participate, they were asked to sign the informed consent and hand-filled the questionnaire on the spot.

Inclusion criteria for this study were as follows: age ≥ 18 years old, no history of mental illness, able to read and understand Bahasa Indonesia. History of mental illness among prospective respondents was ascertained by the registrar by verbally asking them if they had ever been diagnosed with mental illness or any mental health problems in the past.

Ethics approval

This study was conducted in accordance with the guidelines in the Declaration of Helsinki and was approved by the ethical review board of the Faculty of Medicine, Universitas Airlangga prior to study initiation (approval number: 201/EC/KEPK/FKUA/2020; approval date: 19 August 2020). All respondents provided written informed consent prior to their inclusion in the study, and information about the study was given before the consent form was signed. Details that might disclose the identity of the respondents were omitted.

Research instrument

The research instrument used in this study was a questionnaire requesting data on sociodemographic characteristics and responses to the Indonesian version of the Depression Anxiety Stress Scale-21 (DASS-21). Collected sociodemographic data were age, gender, education background, job status, marital status, number of children, and recent self-quarantine history. As this study also aimed to explore the possible risk factors of adverse mental health symptoms, the gathered sociodemographic data were based on literature concerning possible sociodemographic risk factors associated with mental health symptoms during the COVID-19 pandemic [20, 21]. However, since we want to avoid low response rate, we restricted the collection of sociodemographic data to the one that were easily and commonly gathered. DASS-21 is a self-report instrument for evaluating adverse mental health symptoms, which consists of 21 items that assess 3 components, namely symptoms of depression, anxiety, and stress. There are 7 questions for each component, and each question is scored on a 4-point Likert-scale, ranging from 0 (did not apply to me at all / never) to 3 (applied to me very much / almost always). The final score of each component is calculated by multiplying it by a factor of 2. The minimum final score is 0, and the maximum score is 42 for each component. Based on the total score of each component, the responses are categorized as normal, mild, moderate, severe, and extremely severe [36]. The categorization of each component, including the score range, is presented in Table 1. The Indonesian version of DASS-21 had been validated previously and showed good convergence, discriminant validity, and internal consistency (Cronbach’s alpha of 0.895) [37].

Table 1. Categorization and score range of DASS-21 [36].

Normal Mild Moderate Severe Extremely severe
Depression 0–9 10–12 13–20 21–27 28–42
Anxiety 0–6 7–9 10–14 15–19 20–42
Stress 0–10 11–18 19–26 27–34 35–42

Statistical analysis

Data were analyzed using SPSS Statistic for Windows, version 25.0 (IBM Corp., Armonk, N.Y., USA). Data normality was evaluated using one-sample Kolmogorov-Smirnov test and was presented as mean ± standard deviation (SD) for normally distributed data, median [interquartile range (IQR)] for skewed data, and frequency (percentage) for nominal data. To identify the risk factors for depression, anxiety, and stress, two steps logistic regression analysis was used. First, univariate regression was used to identify each sociodemographic variable that was associated with depression, anxiety, and stress. Variables with p-value < 0.25 [38] were then subjected to multivariate regression using backward selection method. Variables with p-value < 0.05 from the multivariate regression analysis were considered as independent risk factors. During the logistic regression analysis, variables with missing data of more than 20% were excluded, and depression, anxiety, and stress variables were re-categorized as dichotomous (normal or not) variables with the cut-off scores as follows: 9 for depression, 6 for anxiety, and 10 for stress [36].

Results

From 778 non-hospitalized asymptomatic and mild COVID-19 patients who came to Indrapura Emergency Field Hospital during the study period, 763 participants fulfilled the inclusion criteria to be enrolled in the study. Of them, 608 patients were included in the analysis (79.7% response rate) (Fig 1). Sociodemographic characteristics of the study participants are presented in Table 2.

Fig 1. Flow diagram of study participants.

Fig 1

Table 2. Sociodemographic characteristic of the study participants.

Variables N = 608
Age in years, median [IQR] 35 [27–45]
Gender, n (%)
Male 372 (61.2)
Female 236 (38.8)
Marital status, n (%)
Married 437 (71.9)
Single 162 (26.6)
Divorced 9 (1.5)
Have a child, n (%)
Yes 335 (55.1)
No 273 (44.9)
Educational background, n (%) *
Elementary graduate 16 (3.8)
Junior high graduate 23 (5.4)
Senior high graduate 207 (48.7)
University graduate 179 (42.1)
Job status as a healthcare worker, n (%) 27 (4.4)
Family income per month, n (%) #
< IDR 4.000.000 168 (41.2)
≥ IDR 4.000.000 240 (58.8)
Had undergone self-quarantine recently, n (%)
Yes 271 (44.6)
No 337 (55.4)

*Missing data on 183 (30.1%) respondents.

#Missing data on 200 (32.9%) respondents.

Median [IQR] score for depression was 0 [0–2], 2 [0–4] for anxiety, and 2 [0–6] for stress. Total score was 4 [0–12]. Of all respondents, 22 (3.6%) reported symptoms of depression, 87 (14.3%) reported symptoms of anxiety, and 48 (7.9%) reported symptoms of stress. Data on the severity of each component is presented in Table 3.

Table 3. Mental health severity symptoms distribution of the study participants.

Depression Anxiety Stress
Normal, n (%) 586 (96.4) 521 (85.7) 560 (92.1)
Mild, n (%) 13 (2.1) 25 (4.1) 46 (7.6)
Moderate, n (%) 8 (1.3) 54 (8.9) 2 (0.3)
Severe, n (%) 1 (0.2) 7 (1.2) 0 (0)
Extremely severe, n (%) 0 (0) 1 (0.2) 0 (0)

For regression analysis, all sociodemographic variables from Table 1 were included, except educational background and family income, as these variables had a high percentage of missing data. Results of univariate and multivariate regression analysis for depression are presented in Table 4. Respondents who worked as HCWs and those who had undergone self-quarantine recently were more likely to report symptoms of depression (Table 4). Table 5 lists the results of regression analysis for anxiety. Respondents who worked as HCWs were more likely to report symptoms of anxiety (Table 5). Univariate and multivariate regression for stress are presented in Table 6. Female respondents and those who had undergone self-quarantine were more likely to report symptoms of stress (Table 6).

Table 4. Univariate and multivariate logistic regression analysis for depression.

Variables Univariate Multivariate
COR 95%CI p-value AOR 95%CI p-value
Gender
Male (ref) - - -
Female 1.60 0.68–3.76 0.277
Age in years 1.01 0.97–1.04 0.720
Marital status
Married (ref) - - -
Single 1.57 0.65–3.82 0.320
Divorced 0.0 0 0.999
Have a child
No (ref) - - -
Yes 0.98 0.42–2.30 0.977
Job status
Healthcare workers 7.54 2.55–22.30 < 0.001 5.57 1.83–16.95 0.002
Other than healthcare workers (ref) - - - - - -
Had undergone self-quarantine recently
No (ref) - - - - - -
Yes 5.92 1.98–17.72 0.001 5.18 1.71–15.69 0.004

Variables with p-value < 0.25 in univariate analysis were subjected to multivariate analysis. Variables with p-value < 0.05 in multivariate analysis were defined as independent risk factors. AOR, adjusted odds ratio; COR, crude odds ratio; 95%CI, 95% confidence interval.

Table 5. Univariate and multivariate logistic regression analysis for anxiety.

Variables Univariate Multivariate
COR 95%CI p-value AOR 95%CI p-value
Gender
Male (ref) - - -
Female 1.57 1.00–2.48 0.052
Age in years 0.99 0.97–1.01 0.550
Marital status
Married (ref) - - -
Single 0.85 0.50–1.45 0.554
Divorced 0.72 0.09–5.82 0.754
Have a child
No (ref) - - -
Yes 1.40 0.88–2.23 0.159
Job status
Healthcare workers 3.22 1.40–7.43 0.006 2.92 1.24–6.88 0.014
Other than healthcare workers (ref) - - - - - -
Had undergone self-quarantine recently
No (ref) - - -
Yes 1.56 0.99–2.46 0.057

Variables with p-value < 0.25 in univariate analysis were subjected to multivariate analysis. Variables with p-value < 0.05 in multivariate analysis were defined as independent risk factors. AOR, adjusted odds ratio; COR, crude odds ratio; 95%CI, 95% confidence interval.

Table 6. Univariate and multivariate logistic regression analysis for stress.

Variables Univariate Multivariate
COR 95%CI p-value AOR 95%CI P-value
Gender
Male (ref) - - - - - -
Female 2.16 1.19–3.92 0.011 1.98 1.08–3.64 0.028
Age in years 1.00 0.97–1.02 0.882
Marital status
Married (ref) - - -
Single 0.92 0.47–1.82 0.808
Divorced 1.44 0.18–11.81 0.737
Have a child
No (ref) - - -
Yes 1.39 0.76–2.56 0.284
Job status
Healthcare workers 3.67 1.40–9.58 0.008
Other than healthcare workers (ref) - - -
Had undergone self-quarantine recently
No (ref) - - - - - -
Yes 2.01 1.10–3.66 0.023 1.86 1.01–3.44 0.047

Variables with p-value < 0.25 in univariate analysis were subjected to multivariate analysis. Variables with p-value < 0.05 in multivariate analysis were defined as independent risk factors. AOR, adjusted odds ratio; COR, crude odds ratio; 95%CI, 95% confidence interval.

Discussion

Our analysis indicates that, in the later period of the COVID-19 pandemic, the prevalence of depression, anxiety, and stress was 3.6%, 14.3%, and 7.9%, respectively, among non-hospitalized asymptomatic and mild COVID-19 patients in the East Java province, Indonesia. Further, we were able to identify job status as HCWs and recent self-quarantine history to be the risk factors for depression, while that for anxiety was job status as HCWs, and those for stress were female gender and recent self-quarantine history.

To the best of our knowledge, there are only 4 studies that evaluate the mental health of non-hospitalized asymptomatic and/or mild COVID-19 patients to this date [33, 3941]. Guo et al (2020) evaluated the mental health symptoms of mild COVID-19 patients in China and revealed that the prevalence of depression and anxiety were 17.5% and 6.8%, respectively. Additionally, compared to matched normal individuals, total score for depression and anxiety were significantly higher in mild COVID-19 patients [39]. In Korea, the prevalence of depression and anxiety among asymptomatic and mild COVID-19 patients were 10.3–24.3% and 14.9–15.9%, respectively [33, 40]. A study among asymptomatic COVID-19 patients from India showed that the prevalence of depression, anxiety, and stress were 49.4%, 40.9%, and 75.8%, respectively [41].

There are several possible explanations for such differences in terms of prevalence rates between this current study and previous studies. First, while our study was done in September 2020, previous studies were done during the initial stage of the pandemic. A recent meta-analysis of a longitudinal cohort studies showed that the prevalence of adverse mental health symptoms was the highest during March–April 2020 and decreased significantly afterward [18]. It is because perceived risks on COVID-19 infection and mortality, financial stability, and lifestyle changes rose sharply in the initial stages of the pandemic and declined in the later stages, and these factors were positively associated with changes in mental health symptoms [42]. Second, as the condition of healthcare systems and the government’s response to the pandemic differ across countries, the prevalence of depression, anxiety, and stress are likely to be lower in countries where both are adequate [43, 44]. Third, the instrument used to measure mental health status in this study is different from those used previously [33, 39, 40], which would have also contributed to the observed variation. For example, compared to DASS-21, 8-item Patient Health Questionnaire instrument is more likely to classify individuals as having depression, while 7-item General Anxiety Disorder instrument is more likely to classify individuals as having anxiety [45]. However, the best instrument to measure depression, anxiety, and stress remains contentious, and we used the DASS-21 because it can measure depression, anxiety, and stress with the least number of questions and has already been adapted to Bahasa Indonesia.

Several studies have evaluated the prevalence of mental health symptoms during the COVID-19 pandemic in Indonesia using DASS-21. However, all of the studies focused on either general population [4648] or healthcare workers [4953], with none on the asymptomatic and/or mild COVID-19 patients. Depending on the study population and data collection period, the prevalence of depression, anxiety, and stress was 8.5–32.6%, 9.3–44.9%, and 2.4–31.8%, respectively [4653]. Other than study period differences that has been discussed in the paragraph above and the difference in study population, varying prevalence rates may also be explained by differences in data collection methods used. While previous studies collected the data using online survey [4652], we directly approached potential respondents and asked them to fill in the questionnaire. When collecting data for mental health studies, it has been reported that respondents provide a more negative response in online surveys than in offline surveys [54]. We hypothesized that this may be due to the anonymity associated with online questionnaires, because the respondents believe that their true identity can be fully protected in online but not in offline surveys. The identity issue might also be associated with societal stigma and discrimination toward people with mental health problems, especially in Asian countries, including Indonesia [5557].

We found that people who worked as HCWs were more likely to report symptoms of depression and anxiety compared to non-HCWs, a finding not consistent with previous reports. For example, a study from China showed that the general population was at greater risk of developing depression and anxiety compared to HCWs [58], and another study from Italy reported that the general population and frontline HCWs were at similar risk of developing depression and anxiety [59]. We posit that disparities in healthcare systems across countries during a pandemic lead to differential impact on the mental health among HCWs [60], and that they are responsible for the observed differences in results.

The capacity of Indonesia’s healthcare system and infrastructure is far from adequate to battle the COVID-19 pandemic. Since before the COVID-19 pandemic, there has been a significant shortage of HCWs and their distribution is uneven throughout the country [61]. However, during the COVID-19 pandemic, the shortage of HCWs is aggravated by high mortality among those treating COVID-19 patients [62, 63], resulting in higher workload and longer working hours for the remaining personnel, especially when the number of COVID-19 patients continue to increase. Moreover, similar to other countries, there is a lack of personal protective equipment (PPE) for HCWs on duty in Indonesia, with this shortage being worsened by the panic buying and stockpiling of medical-grade PPE by the public [63, 64]. Other than that, the number of hospitals, bed capacities, and supporting facilities to treat COVID-19 patients such as negative pressure wards and ICU rooms are lacking and also not evenly distributed in Indonesia [6163]. The lack of facilities putting HCWs in difficult position, where they have to decide to whom the treatments should be given [65]. The above-mentioned issues might explain why HCWs in Indonesia are more prone to adverse mental health symptoms compared to the general population.

In our study, we discovered that women were more likely to report symptoms of stress, and previous studies, either before [6669] or during the COVID-19 pandemic [48, 7072], also showed that women register higher stress scores and are at greater risk of developing stress. Gender differences in mental health have been discussed since the 1970s, and women have been reported to experience distress more frequently and develop more symptoms than men under identical levels of stress [73]. Several explanations have been proposed for greater stress susceptibility in women. Biologically, women express higher levels of corticotropin-releasing factor (CRF) and had more CRF receptors compared to men, and upon its release from the hypothalamus during a stressful event, CRF activates the hypothalamus-pituitary-adrenal axis by stimulating adrenocorticotropic hormone (ACTH) to produce cortisol, which is a primary stress hormone in the body, from the adrenal cortex [74]. Additionally, at identical levels of ACTH, the female adrenal cortex is more responsive to cortisol production than the male adrenal cortex [75]. Furthermore, fluctuations in sex hormones, either due to menstrual cycle or reproductive status, also contribute to stress vulnerability [76]. Psychologically, women tend to express distress by internalizing problems rather than externalizing them [77]. Apart from that, as women are the primary caregivers within the household, and they often prioritize the condition of family members over their own [78, 79]. During the COVID-19 pandemic, it can be assumed that they may be apprehensive of no one being able to take care of the family if they are diagnosed with COVID-19 and had to be quarantined or hospitalized.

Interestingly, although mental health problems appear to be more common in women, suicide rates have been noted to be higher in men [8082]. It can then be argued that mental health problems are underdiagnosed in men. Several possible explanations have been proposed, and they include: 1) men are less likely to express troubles, discuss sensitive issues, or solve emotional problems [83]; 2) men are more likely to express the distress by externalizing problems rather than internalizing them because of the fear of stigma [77]; and 3) men seek help for mental health care far less often than women as help-seeking behavior is viewed as a weakness and is contrary to masculine traits [84, 85]. In addition to that, it has also been suggested that there is a measurement bias in the currently available self-report instrument for mental health [83]. For instance, the experience of stress is different between sexes, where men feel more depersonalized, while women tend to feel emotionally exhausted [86]. Nevertheless, available instruments to measure stress do not assess psychological stress as depersonalization [68]. Thus, although the current study and a great body of evidence support the notion that women are at higher risk of developing mental health symptoms, we believe that investigations using structured diagnostic interviews should be done in the future to clarify whether one gender is at higher risk of developing mental health symptoms than the other.

In this study, we also found that people who had undergone self-quarantine recently were more likely to report symptoms of depression and stress. Since the 14th century, quarantine has been an important public health measure to reduce incidence and mortality during any outbreak [87, 88]. However, quarantine negatively affects mental health, and data from previous outbreaks have described several adverse psychological effects such as depression, anxiety, stress, low mood, and anger [89]. A recently published meta-analysis revealed a significant relationship between mass quarantine and mental health during the COVID-19 pandemic [90], and a multi-center study from 7 middle-income countries in Asia showed that those who have ever been quarantined during the COVID-19 pandemic were at higher risk of depression, anxiety, and stress [11]. Studies from China also demonstrate that people who were quarantined had higher risk of depression, anxiety, and stress. Furthermore, those who were diagnosed or suspected of having COVID-19 infection were at even greater risk of depression, anxiety, and stress compared to uninfected individuals [21, 91].

Nevertheless, the negative effects of quarantine on mental health appears to occur only during self-quarantine and not in facilitated quarantine. In the initial stage of the pandemic, Jeong et al (2020) evaluated the mental health of asymptomatic and mildly symptomatic COVID-19 patients who were admitted to the non-hospital facilities for isolation and monitoring in South Korea. Mental health status was evaluated twice in that study, i.e., after the 2nd week of quarantine and 1 week after the first survey, and they found no significant differences in anxiety or depression scores [33]. A similar study from South Korea also found that the prevalence of depression, anxiety, suicidal risk, and stress was constant until the 4th week of quarantine [40]. We have also previously reported that being quarantined in a quarantine facility did not worsen the mental health status of asymptomatic and mild COVID-19 patients [92]. Some of the known psychological stressors during quarantine are frustration, boredom, and inadequate supplies [89], but in a quarantine facility, patients are provided free meals thrice daily, including snacks and entertainment facilities. In contrast, people who undergo self-quarantine are not provided such things by the government, and this might explain these differences in terms of mental health status.

This study has several important limitations. First, the symptoms of depression, anxiety, and stress were based on self-reported questionnaire; hence, they may not always concur with objective assessment by health professionals. Second, the cross-sectional nature of this study precludes any inference of causality or evaluation of longitudinal changes in mental health symptoms during the COVID-19 pandemic. Third, socioeconomic status and educational background were not included in the regression model due to the missing data in more than 30% of the respondents. Fourth, it has been shown that longer quarantine time was associated with worsen mental health status [90, 93]. However, data regarding the number of days in self-quarantine were not available for a majority of the respondents because they could not adequately recall relevant details. Fifth, we did not evaluate the mental health prevalence from other groups, e.g., general population, hospitalized COVID-19 patients, and long COVID-19 patients. Thus, difference in mental health symptoms prevalence between non-hospitalized asymptomatic and mild COVID-19 patients and other groups could not be seen. Last, data collection for this study was done in September 2020. The situation in that period was different than when Indonesia became the epicentrum of the COVID-19 pandemic in Asia [94], or in the recent outbreak of the Omicron variant [95].

Conclusion

To the best of our knowledge, this is the first study to investigate the mental health symptoms among non-hospitalized asymptomatic and mild COVID-19 patients during the later period of the COVID-19 pandemic. We report that the prevalence of mental health symptoms, especially depression, is relatively low among these patients in East Java province, Indonesia. Despite the low prevalence, our finding showed that HCWs are more vulnerable to depression and anxiety; females are more vulnerable to stress; and those who had undergone self-quarantine recently are more vulnerable to depression and stress.

Supporting information

S1 Raw data

(SAV)

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

The authors received no specific funding for this work.

References

  • 1.World Health Organization. Rolling updates on coronavirus disease (COVID-19) 2020. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen.
  • 2.World Health Organization. Weekly epidemiological update on COVID-19–5 April 2022 [updated 5 April 2022]. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19—5-april-2022.
  • 3.Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91–8. Epub 2020/04/08. doi: 10.1016/j.jare.2020.03.005 ; PubMed Central PMCID: PMC7113610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Ganesan B, Al-Jumaily A, Fong KNK, Prasad P, Meena SK, Tong RK. Impact of Coronavirus Disease 2019 (COVID-19) Outbreak Quarantine, Isolation, and Lockdown Policies on Mental Health and Suicide. Front Psychiatry. 2021;12:565190. Epub 2021/05/04. doi: 10.3389/fpsyt.2021.565190 ; PubMed Central PMCID: PMC8085354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Marazziti D, Stahl SM. The relevance of COVID-19 pandemic to psychiatry. World Psychiatry. 2020;19(2):261. Epub 2020/05/13. doi: 10.1002/wps.20764 ; PubMed Central PMCID: PMC7215065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Covid- Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398(10312):1700–12. Epub 2021/10/12. doi: 10.1016/S0140-6736(21)02143-7 ; PubMed Central PMCID: PMC8500697 Flaxman holds stock in Agathos, and consults and advises Janssen, SwissRe, Sanofi, and Merck for Mothers on simulation modeling, outside of the submitted work. S Nomura reports support from the Ministry of Education, Culture, Sports, Science and Technology of Japan. All other authors declare no competing interests. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Presti G, McHugh L, Gloster A, Karekla M, Hayes SC. The Dynamics of Fear at the Time of Covid-19: A Contextual Behavioral Science Perspective. Clin Neuropsychiatry. 2020;17(2):65–71. Epub 2020/04/01. doi: 10.36131/CN20200206 ; PubMed Central PMCID: PMC8629087. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Tran BX, Ha GH, Nguyen LH, Vu GT, Hoang MT, Le HT, et al. Studies of Novel Coronavirus Disease 19 (COVID-19) Pandemic: A Global Analysis of Literature. International journal of environmental research and public health. 2020;17(11). Epub 2020/06/12. doi: 10.3390/ijerph17114095 ; PubMed Central PMCID: PMC7312200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.de Sousa GM, Tavares VDO, de Meiroz Grilo MLP, Coelho MLG, de Lima-Araujo GL, Schuch FB, et al. Mental Health in COVID-19 Pandemic: A Meta-Review of Prevalence Meta-Analyses. Front Psychol. 2021;12:703838. Epub 2021/10/09. doi: 10.3389/fpsyg.2021.703838 ; PubMed Central PMCID: PMC8490780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.World Health Organization. Depression and other common mental disorders: global health estimates. Geneva: World Health Organization, 2017. 2017. Report No.: Contract No.: WHO/MSD/MER/2017.2. [Google Scholar]
  • 11.Wang C, Tee M, Roy AE, Fardin MA, Srichokchatchawan W, Habib HA, et al. The impact of COVID-19 pandemic on physical and mental health of Asians: A study of seven middle-income countries in Asia. PLoS One. 2021;16(2):e0246824. Epub 2021/02/12. doi: 10.1371/journal.pone.0246824 ; PubMed Central PMCID: PMC7877638. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Krishnamoorthy Y, Nagarajan R, Saya GK, Menon V. Prevalence of psychological morbidities among general population, healthcare workers and COVID-19 patients amidst the COVID-19 pandemic: A systematic review and meta-analysis. Psychiatry Res. 2020;293:113382. Epub 2020/08/24. doi: 10.1016/j.psychres.2020.113382 ; PubMed Central PMCID: PMC7417292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Nagasu M, Muto K, Yamamoto I. Impacts of anxiety and socioeconomic factors on mental health in the early phases of the COVID-19 pandemic in the general population in Japan: A web-based survey. PLoS One. 2021;16(3):e0247705. Epub 2021/03/18. doi: 10.1371/journal.pone.0247705 ; PubMed Central PMCID: PMC7968643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Dragioti E, Li H, Tsitsas G, Lee KH, Choi J, Kim J, et al. A large-scale meta-analytic atlas of mental health problems prevalence during the COVID-19 early pandemic. J Med Virol. 2021. Epub 2021/12/28. doi: 10.1002/jmv.27549 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Zhang SX, Chen J. Scientific evidence on mental health in key regions under the COVID-19 pandemic—meta-analytical evidence from Africa, Asia, China, Eastern Europe, Latin America, South Asia, Southeast Asia, and Spain. Eur J Psychotraumatol. 2021;12(1):2001192. Epub 2021/12/14. doi: 10.1080/20008198.2021.2001192 ; PubMed Central PMCID: PMC8654399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Liu X, Zhu M, Zhang R, Zhang J, Zhang C, Liu P, et al. Public mental health problems during COVID-19 pandemic: a large-scale meta-analysis of the evidence. Transl Psychiatry. 2021;11(1):384. Epub 2021/07/11. doi: 10.1038/s41398-021-01501-9 ; PubMed Central PMCID: PMC8266633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Cenat JM, Blais-Rochette C, Kokou-Kpolou CK, Noorishad PG, Mukunzi JN, McIntee SE, et al. Prevalence of symptoms of depression, anxiety, insomnia, posttraumatic stress disorder, and psychological distress among populations affected by the COVID-19 pandemic: A systematic review and meta-analysis. Psychiatry Res. 2021;295:113599. Epub 2020/12/08. doi: 10.1016/j.psychres.2020.113599 ; PubMed Central PMCID: PMC7689353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Robinson E, Sutin AR, Daly M, Jones A. A systematic review and meta-analysis of longitudinal cohort studies comparing mental health before versus during the COVID-19 pandemic in 2020. J Affect Disord. 2022;296:567–76. Epub 2021/10/04. doi: 10.1016/j.jad.2021.09.098 ; PubMed Central PMCID: PMC8578001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Mahmud S, Mohsin M, Dewan MN, Muyeed A. The Global Prevalence of Depression, Anxiety, Stress, and Insomnia Among General Population During COVID-19 Pandemic: A Systematic Review and Meta-analysis. Trends in Psychology. 2022. doi: 10.1007/s43076-021-00116-9 [DOI] [Google Scholar]
  • 20.Gonzalez-Sanguino C, Ausin B, Castellanos MA, Saiz J, Lopez-Gomez A, Ugidos C, et al. Mental health consequences during the initial stage of the 2020 Coronavirus pandemic (COVID-19) in Spain. Brain, behavior, and immunity. 2020;87:172–6. Epub 2020/05/15. doi: 10.1016/j.bbi.2020.05.040 ; PubMed Central PMCID: PMC7219372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Shi L, Lu ZA, Que JY, Huang XL, Liu L, Ran MS, et al. Prevalence of and Risk Factors Associated With Mental Health Symptoms Among the General Population in China During the Coronavirus Disease 2019 Pandemic. JAMA Netw Open. 2020;3(7):e2014053. Epub 2020/07/02. doi: 10.1001/jamanetworkopen.2020.14053 ; PubMed Central PMCID: PMC7330717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Ngasa SN, Tchouda LAS, Abanda C, Ngasa NC, Sanji EW, Dingana TN, et al. Prevalence and factors associated with anxiety and depression amongst hospitalised COVID-19 patients in Laquintinie Hospital Douala, Cameroon. PLoS One. 2021;16(12):e0260819. Epub 2021/12/03. doi: 10.1371/journal.pone.0260819 ; PubMed Central PMCID: PMC8638855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Sahan E, Unal SM, Kirpinar I. Can we predict who will be more anxious and depressed in the COVID-19 ward? J Psychosom Res. 2021;140:110302. Epub 2020/12/03. doi: 10.1016/j.jpsychores.2020.110302 ; PubMed Central PMCID: PMC7683951. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Xie Y, Xu E, Al-Aly Z. Risks of mental health outcomes in people with covid-19: cohort study. BMJ. 2022;376:e068993. doi: 10.1136/bmj-2021-068993 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Magnúsdóttir I, Lovik A, Unnarsdóttir AB, McCartney D, Ask H, Kõiv K, et al. Acute COVID-19 severity and mental health morbidity trajectories in patient populations of six nations: an observational study. The Lancet Public Health. 2022. doi: 10.1016/S2468-2667(22)00042-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Lechien JR, Chiesa-Estomba CM, Place S, Van Laethem Y, Cabaraux P, Mat Q, et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med. 2020;288(3):335–44. Epub 2020/05/01. doi: 10.1111/joim.13089 ; PubMed Central PMCID: PMC7267446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Ma YF, Li W, Deng HB, Wang L, Wang Y, Wang PH, et al. Prevalence of depression and its association with quality of life in clinically stable patients with COVID-19. J Affect Disord. 2020;275:145–8. Epub 2020/07/14. doi: 10.1016/j.jad.2020.06.033 ; PubMed Central PMCID: PMC7329672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Veazie S, Lafavor B, Vela K, Young S, Sayer NA, Carlson KF, et al. Mental health outcomes of adults hospitalized for COVID-19: A systematic review. J Affect Disord Rep. 2022;8:100312. Epub 2022/02/16. doi: 10.1016/j.jadr.2022.100312 ; PubMed Central PMCID: PMC8828444. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–42. Epub 2020/02/25. doi: 10.1001/jama.2020.2648 . [DOI] [PubMed] [Google Scholar]
  • 30.Lechien JR, Chiesa-Estomba CM, Vaira LA, De Riu G, Cammaroto G, Chekkoury-Idrissi Y, et al. Epidemiological, otolaryngological, olfactory and gustatory outcomes according to the severity of COVID-19: a study of 2579 patients. Eur Arch Otorhinolaryngol. 2021;278(8):2851–9. Epub 2021/01/17. doi: 10.1007/s00405-020-06548-w ; PubMed Central PMCID: PMC7811338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Shoaib N, Noureen N, Munir R, Shah FA, Ishtiaq N, Jamil N, et al. COVID-19 severity: Studying the clinical and demographic risk factors for adverse outcomes. PLoS One. 2021;16(8):e0255999. Epub 2021/08/12. doi: 10.1371/journal.pone.0255999 ; PubMed Central PMCID: PMC8357125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Bennett TD, Moffitt RA, Hajagos JG, Amor B, Anand A, Bissell MM, et al. Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort Collaborative. JAMA Netw Open. 2021;4(7):e2116901. Epub 2021/07/14. doi: 10.1001/jamanetworkopen.2021.16901 ; PubMed Central PMCID: PMC8278272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Jeong SJ, Chung WS, Sohn Y, Hyun JH, Baek YJ, Cho Y, et al. Clinical characteristics and online mental health care of asymptomatic or mildly symptomatic patients with coronavirus disease 2019. PLoS One. 2020;15(11):e0242130. Epub 2020/11/24. doi: 10.1371/journal.pone.0242130 ; PubMed Central PMCID: PMC7682865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.World Health Organization Indonesia. Coronavirus Disease 2019 (COVID-19) Situation Report—27 2020 [updated 30 September 2020]. Available from: https://cdn.who.int/media/docs/default-source/searo/indonesia/who-situation-report-27_f1cd3a6e-afe4-43ab-bd4f-d3f460b321de.pdf?sfvrsn=ce8d437a_4.
  • 35.Indonesian COVID-19 operational Taskforce. Peta Sebaran 2020. Available from: https://covid19.go.id/peta-sebaran.
  • 36.Lovibond SH, Lovibond PF. Manual for the Depression Anxiety Stress Scales. 2nd ed. Sydney Australia: Psychology Foundation; 1995. [Google Scholar]
  • 37.El-Matury HJ, Lestari FA, Besral. Depression, anxiety and stress among undergraduate students in jakarta: Examining scores of the depression anxiety and stress scale according to origin and residency. Indian Journal of Public Health Research and Development. 2018;9(2):290–5. [Google Scholar]
  • 38.Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008;3:17. Epub 2008/12/18. doi: 10.1186/1751-0473-3-17 ; PubMed Central PMCID: PMC2633005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Guo Q, Zheng Y, Shi J, Wang J, Li G, Li C, et al. Immediate psychological distress in quarantined patients with COVID-19 and its association with peripheral inflammation: A mixed-method study. Brain, behavior, and immunity. 2020;88:17–27. Epub 2020/05/18. doi: 10.1016/j.bbi.2020.05.038 ; PubMed Central PMCID: PMC7235603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Kang E, Lee SY, Kim MS, Jung H, Kim KH, Kim KN, et al. The Psychological Burden of COVID-19 Stigma: Evaluation of the Mental Health of Isolated Mild Condition COVID-19 Patients. J Korean Med Sci. 2021;36(3):e33. Epub 2021/01/20. doi: 10.3346/jkms.2021.36.e33 ; PubMed Central PMCID: PMC7813581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Upadhyay R, Sweta Singh B, Singh U. Psychological impact of quarantine period on asymptomatic individuals with COVID-19. Soc Sci Humanit Open. 2020;2(1):100061. Epub 2020/01/01. doi: 10.1016/j.ssaho.2020.100061 ; PubMed Central PMCID: PMC7474906. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Robinson E, Daly M. Explaining the rise and fall of psychological distress during the COVID-19 crisis in the United States: Longitudinal evidence from the Understanding America Study. Br J Health Psychol. 2021;26(2):570–87. Epub 2020/12/06. doi: 10.1111/bjhp.12493 . [DOI] [PubMed] [Google Scholar]
  • 43.Paz C, Mascialino G, Adana-Diaz L, Rodriguez-Lorenzana A, Simbana-Rivera K, Gomez-Barreno L, et al. Anxiety and depression in patients with confirmed and suspected COVID-19 in Ecuador. Psychiatry and clinical neurosciences. 2020. doi: 10.1111/pcn.13106 ; PubMed Central PMCID: PMC7361296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Maekelae MJ, Reggev N, Dutra N, Tamayo RM, Silva-Sobrinho RA, Klevjer K, et al. Perceived efficacy of COVID-19 restrictions, reactions and their impact on mental health during the early phase of the outbreak in six countries. R Soc Open Sci. 2020;7(8):200644. Epub 2020/09/25. doi: 10.1098/rsos.200644 ; PubMed Central PMCID: PMC7481706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Peters L, Peters A, Andreopoulos E, Pollock N, Pande RL, Mochari-Greenberger H. Comparison of DASS-21, PHQ-8, and GAD-7 in a virtual behavioral health care setting. Heliyon. 2021;7(3):e06473. Epub 2021/04/06. doi: 10.1016/j.heliyon.2021.e06473 ; PubMed Central PMCID: PMC8010403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Harjana NPA, Januraga PP, Indrayathi PA, Gesesew HA, Ward PR. Prevalence of Depression, Anxiety, and Stress Among Repatriated Indonesian Migrant Workers During the COVID-19 Pandemic. Front Public Health. 2021;9:630295. Epub 2021/05/25. doi: 10.3389/fpubh.2021.630295 ; PubMed Central PMCID: PMC8131639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.d’Arqom A, Sawitri B, Nasution Z, Lazuardi R. "Anti-COVID-19" Medications, Supplements, and Mental Health Status in Indonesian Mothers with School-Age Children. Int J Womens Health. 2021;13:699–709. Epub 2021/07/22. doi: 10.2147/IJWH.S316417 ; PubMed Central PMCID: PMC8286101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Elvira SD, Lamuri A, Lukman PR, Malik K, Shatri H, Abdullah M. Psychological distress among Greater Jakarta area residents during the COVID-19 pandemic and community containment. Heliyon. 2021;7(2):e06289. Epub 2021/02/23. doi: 10.1016/j.heliyon.2021.e06289 ; PubMed Central PMCID: PMC7879033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Marthoenis Maskur, Fathiariani L, Nassimbwa J. Investigating the burden of mental distress among nurses at a provincial COVID-19 referral hospital in Indonesia: a cross-sectional study. BMC Nurs. 2021;20(1):76. Epub 2021/05/14. doi: 10.1186/s12912-021-00596-1 ; PubMed Central PMCID: PMC8114658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Lugito NPH, Kurniawan A, Lorens JO, Sieto NL. Mental health problems in Indonesian internship doctors during the COVID-19 pandemic. J Affect Disord Rep. 2021;6:100283. Epub 2021/12/14. doi: 10.1016/j.jadr.2021.100283 ; PubMed Central PMCID: PMC8642719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Sitanggang FP, Wirawan GBS, Wirawan IMA, Lesmana CBJ, Januraga PP. Determinants of Mental Health and Practice Behaviors of General Practitioners During COVID-19 Pandemic in Bali, Indonesia: A Cross-sectional Study. Risk Manag Healthc Policy. 2021;14:2055–64. Epub 2021/05/28. doi: 10.2147/RMHP.S305373 ; PubMed Central PMCID: PMC8141387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Margaretha SEP, Effendy C, Kusnanto H, Hasinuddin M. Determinants psychological distress of Indonesian Health Care Providers During COVID-19 Pandemic. Sys Rev Pharm. 2020;11(6):1052–9. doi: 10.31838/srp.2020.6.150 [DOI] [Google Scholar]
  • 53.Syamlan AT, Salamah S, Alkaff FF, Prayudi YE, Kamil M, Irzaldy A, et al. Mental health and health-related quality of life among healthcare workers in Indonesia during the COVID-19 pandemic: a cross-sectional study. BMJ Open. 2022;12(4):e057963. doi: 10.1136/bmjopen-2021-057963 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Zhang X, Kuchinke L, Woud ML, Velten J, Margraf J. Survey method matters: Online/offline questionnaires and face-to-face or telephone interviews differ. Computers in Human Behavior. 2017;71:172–80. 10.1016/j.chb.2017.02.006. [DOI] [Google Scholar]
  • 55.Lauber C, Rossler W. Stigma towards people with mental illness in developing countries in Asia. Int Rev Psychiatry. 2007;19(2):157–78. Epub 2007/04/28. doi: 10.1080/09540260701278903 . [DOI] [PubMed] [Google Scholar]
  • 56.Henderson C, Evans-Lacko S, Thornicroft G. Mental illness stigma, help seeking, and public health programs. Am J Public Health. 2013;103(5):777–80. Epub 2013/03/16. doi: 10.2105/AJPH.2012.301056 ; PubMed Central PMCID: PMC3698814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Hartini N, Fardana NA, Ariana AD, Wardana ND. Stigma toward people with mental health problems in Indonesia. Psychol Res Behav Manag. 2018;11:535–41. Epub 2018/11/23. doi: 10.2147/PRBM.S175251 ; PubMed Central PMCID: PMC6217178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.He Q, Fan B, Xie B, Liao Y, Han X, Chen Y, et al. Mental health conditions among the general population, healthcare workers and quarantined population during the coronavirus disease 2019 (COVID-19) pandemic. Psychology, health & medicine. 2020:1–13. Epub 2020/12/31. doi: 10.1080/13548506.2020.1867320 . [DOI] [PubMed] [Google Scholar]
  • 59.Rossi R, Socci V, Pacitti F, Mensi S, Di Marco A, Siracusano A, et al. Mental Health Outcomes Among Healthcare Workers and the General Population During the COVID-19 in Italy. Front Psychol. 2020;11:608986. Epub 2020/12/29. doi: 10.3389/fpsyg.2020.608986 ; PubMed Central PMCID: PMC7753010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Uphoff EP, Lombardo C, Johnston G, Weeks L, Rodgers M, Dawson S, et al. Mental health among healthcare workers and other vulnerable groups during the COVID-19 pandemic and other coronavirus outbreaks: A rapid systematic review. PLOS ONE. 2021;16(8):e0254821. doi: 10.1371/journal.pone.0254821 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Mahendradhata Y, Andayani N, Hasri ET, Arifi MD, Siahaan RGM, Solikha DA, et al. The Capacity of the Indonesian Healthcare System to Respond to COVID-19. Front Public Health. 2021;9:649819. Epub 2021/07/27. doi: 10.3389/fpubh.2021.649819 ; PubMed Central PMCID: PMC8292619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Wirawan GBS, Januraga PP. Correlation of Demographics, Healthcare Availability, and COVID-19 Outcome: Indonesian Ecological Study. Front Public Health. 2021;9:605290. Epub 2021/02/19. doi: 10.3389/fpubh.2021.605290 ; PubMed Central PMCID: PMC7882903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Yunus F, Andarini S. Letter from Indonesia. Respirology. 2020;25(12):1328–9. Epub 2020/10/09. doi: 10.1111/resp.13953 . [DOI] [PubMed] [Google Scholar]
  • 64.Lauren C, Iskandar A, Argie D, Malelak EB, Sebayang SES, Mawardy R, et al. Strategy within limitations during COVID-19 pandemic in Indonesia: Shortage of PPE, prevention, and neurosurgery practice. 2020. 2020;9(3):3. Epub 2020-09-26. doi: 10.15562/bmj.v9i3.1825 [DOI] [Google Scholar]
  • 65.Emanuel EJ, Persad G, Upshur R, Thome B, Parker M, Glickman A, et al. Fair Allocation of Scarce Medical Resources in the Time of Covid-19. N Engl J Med. 2020;382(21):2049–55. Epub 2020/03/24. doi: 10.1056/NEJMsb2005114 . [DOI] [PubMed] [Google Scholar]
  • 66.Nielsen L, Curtis T, Kristensen TS, Rod Nielsen N. What characterizes persons with high levels of perceived stress in Denmark? A national representative study. Scand J Public Health. 2008;36(4):369–79. Epub 2008/06/10. doi: 10.1177/1403494807088456 . [DOI] [PubMed] [Google Scholar]
  • 67.Cohen S, Janicki-Deverts D. Who’s Stressed? Distributions of Psychological Stress in the United States in Probability Samples from 1983, 2006, and 20091. Journal of Applied Social Psychology. 2012;42(6):1320–34. doi: 10.1111/j.1559-1816.2012.00900.x [DOI] [Google Scholar]
  • 68.Klein EM, Brahler E, Dreier M, Reinecke L, Muller KW, Schmutzer G, et al. The German version of the Perceived Stress Scale—psychometric characteristics in a representative German community sample. BMC Psychiatry. 2016;16:159. Epub 2016/05/25. doi: 10.1186/s12888-016-0875-9 ; PubMed Central PMCID: PMC4877813. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Costa C, Briguglio G, Mondello S, Teodoro M, Pollicino M, Canalella A, et al. Perceived Stress in a Gender Perspective: A Survey in a Population of Unemployed Subjects of Southern Italy. Front Public Health. 2021;9:640454. Epub 2021/04/20. doi: 10.3389/fpubh.2021.640454 ; PubMed Central PMCID: PMC8046934. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Gloster AT, Lamnisos D, Lubenko J, Presti G, Squatrito V, Constantinou M, et al. Impact of COVID-19 pandemic on mental health: An international study. PLoS One. 2020;15(12):e0244809. Epub 2021/01/01. doi: 10.1371/journal.pone.0244809 ; PubMed Central PMCID: PMC7774914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Al Dhaheri AS, Bataineh MF, Mohamad MN, Ajab A, Al Marzouqi A, Jarrar AH, et al. Impact of COVID-19 on mental health and quality of life: Is there any effect? A cross-sectional study of the MENA region. PLoS One. 2021;16(3):e0249107. Epub 2021/03/26. doi: 10.1371/journal.pone.0249107 ; PubMed Central PMCID: PMC7993788. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Gu Y, Zhu Y, Xu F, Xi J, Xu G. Factors associated with mental health outcomes among patients with COVID-19 treated in the Fangcang shelter hospital in China. Asia Pac Psychiatry. 2021;13(2):e12443. Epub 2020/11/03. doi: 10.1111/appy.12443 . [DOI] [PubMed] [Google Scholar]
  • 73.Weissman MM, Klerman GL. Sex differences and the epidemiology of depression. Arch Gen Psychiatry. 1977;34(1):98–111. Epub 1977/01/01. doi: 10.1001/archpsyc.1977.01770130100011 [DOI] [PubMed] [Google Scholar]
  • 74.Bangasser DA, Wiersielis KR. Sex differences in stress responses: a critical role for corticotropin-releasing factor. Hormones (Athens). 2018;17(1):5–13. Epub 2018/06/03. doi: 10.1007/s42000-018-0002-z . [DOI] [PubMed] [Google Scholar]
  • 75.Roelfsema F, van den Berg G, Frolich M, Veldhuis JD, van Eijk A, Buurman MM, et al. Sex-dependent alteration in cortisol response to endogenous adrenocorticotropin. J Clin Endocrinol Metab. 1993;77(1):234–40. Epub 1993/07/01. doi: 10.1210/jcem.77.1.8392084 [DOI] [PubMed] [Google Scholar]
  • 76.Li SH, Graham BM. Why are women so vulnerable to anxiety, trauma-related and stress-related disorders? The potential role of sex hormones. Lancet Psychiatry. 2017;4(1):73–82. Epub 2016/11/20. doi: 10.1016/S2215-0366(16)30358-3 . [DOI] [PubMed] [Google Scholar]
  • 77.Simon RW. Sociological Scholarship on Gender Differences in Emotion and Emotional Well-Being in the United States: A Snapshot of the Field. Emotion Review. 2014;6(3):196–201. doi: 10.1177/1754073914522865 [DOI] [Google Scholar]
  • 78.Langer A, Meleis A, Knaul FM, Atun R, Aran M, Arreola-Ornelas H, et al. Women and Health: the key for sustainable development. Lancet. 2015;386(9999):1165–210. Epub 2015/06/09. doi: 10.1016/S0140-6736(15)60497-4 . [DOI] [PubMed] [Google Scholar]
  • 79.Rahman MA, Islam SMS, Tungpunkom P, Sultana F, Alif SM, Banik B, et al. COVID-19: Factors associated with psychological distress, fear, and coping strategies among community members across 17 countries. Globalization and health. 2021;17(1):117. doi: 10.1186/s12992-021-00768-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Freeman A, Mergl R, Kohls E, Szekely A, Gusmao R, Arensman E, et al. A cross-national study on gender differences in suicide intent. BMC Psychiatry. 2017;17(1):234. Epub 2017/07/01. doi: 10.1186/s12888-017-1398-8 ; PubMed Central PMCID: PMC5492308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: World Health Organization, 2017. [Google Scholar]
  • 82.Ellison JM, Semlow AR, Jaeger EC, Griffth DM. COVID-19 and MENtal Health: Addressing Men’s Mental Health Needs in the Digital World. Am J Mens Health. 2021;15(4):15579883211030021. Epub 2021/07/08. doi: 10.1177/15579883211030021 ; PubMed Central PMCID: PMC8267042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Smith DT, Mouzon DM, Elliott M. Reviewing the Assumptions About Men’s Mental Health: An Exploration of the Gender Binary. Am J Mens Health. 2018;12(1):78–89. Epub 2016/02/13. doi: 10.1177/1557988316630953 ; PubMed Central PMCID: PMC5734543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Oliver MI, Pearson N, Coe N, Gunnell D. Help-seeking behaviour in men and women with common mental health problems: cross-sectional study. Br J Psychiatry. 2005;186:297–301. Epub 2005/04/02. doi: 10.1192/bjp.186.4.297 . [DOI] [PubMed] [Google Scholar]
  • 85.Addis ME, Mahalik JR. Men, masculinity, and the contexts of help seeking. Am Psychol. 2003;58(1):5–14. Epub 2003/04/05. doi: 10.1037/0003-066x.58.1.5 . [DOI] [PubMed] [Google Scholar]
  • 86.Purvanova RK, Muros JP. Gender differences in burnout: A meta-analysis. Journal of Vocational Behavior. 2010;77(2):168–85. doi: 10.1016/j.jvb.2010.04.006 [DOI] [Google Scholar]
  • 87.Nussbaumer-Streit B, Mayr V, Dobrescu AI, Chapman A, Persad E, Klerings I, et al. Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. Cochrane Database Syst Rev. 2020;9:CD013574. Epub 2021/05/08. doi: 10.1002/14651858.CD013574.pub2 ; PubMed Central PMCID: PMC8133397. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Tognotti E. Lessons from the history of quarantine, from plague to influenza A. Emerg Infect Dis. 2013;19(2):254–9. Epub 2013/01/25. doi: 10.3201/eid1902.120312 ; PubMed Central PMCID: PMC3559034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020;395(10227):912–20. Epub 2020/03/01. doi: 10.1016/S0140-6736(20)30460-8 ; PubMed Central PMCID: PMC7158942. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Jin Y, Sun T, Zheng P, An J. Mass quarantine and mental health during COVID-19: A meta-analysis. J Affect Disord. 2021;295:1335–46. Epub 2021/10/29. doi: 10.1016/j.jad.2021.08.067 ; PubMed Central PMCID: PMC8674683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Wang Y, Shi L, Que J, Lu Q, Liu L, Lu Z, et al. The impact of quarantine on mental health status among general population in China during the COVID-19 pandemic. Mol Psychiatry. 2021;26(9):4813–22. Epub 2021/01/24. doi: 10.1038/s41380-021-01019-y ; PubMed Central PMCID: PMC7821451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Lusida MAP, Salamah S, Jonatan M, Syamlan AT, Bandem I, Rahmania AA, et al. The Impact of Facilitated Quarantine on Mental Health Status of Non-Severe COVID-19 Patients. Disaster Med Public Health Prep. 2021:1–2. Epub 2021/11/26. doi: 10.1017/dmp.2021.344 ; PubMed Central PMCID: PMC8692842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Hawryluck L, Gold WL, Robinson S, Pogorski S, Galea S, Styra R. SARS control and psychological effects of quarantine, Toronto, Canada. Emerg Infect Dis. 2004;10(7):1206–12. Epub 2004/08/25. doi: 10.3201/eid1007.030703 ; PubMed Central PMCID: PMC3323345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Dyer O. Covid-19: Indonesia becomes Asia’s new pandemic epicentre as delta variant spreads. BMJ. 2021;374:n1815. doi: 10.1136/bmj.n1815 [DOI] [PubMed] [Google Scholar]
  • 95.Rahadiana R, Jiao C. Indonesia Virus Cases Reach 6-Month High as Omicron Spreads: Bloomberg; 2022 Feb 4 [cited 2022 February 6]. Available from: https://www.bloomberg.com/news/articles/2022-02-03/indonesia-virus-cases-reach-six-month-high-as-omicron-spreads.

Decision Letter 0

Peter G van der Velden

21 Oct 2021

PONE-D-21-21429Prevalence and risk factor for depression, anxiety, and stress in confirmed non-severe COVID-19 patients in East Java province Indonesia

PLOS ONE

Dear Dr. Salamah,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

I have read your manuscript with interest and received the comments of two independent reviewers. The comments of the reviewers are attached in this letter. I agree with their very critical comments and will try to prevent repeating them as much as possible. 

  1. My general impression is that a lot of work needs to be done to address the comments of the reviewers and to address my comments. I would like to advise you strongly to ask a native speaker to check/correct the revised manuscript (the language errors distract too much).

  2. Your introduction lacks, given your research question, a clear overview of what is (un)known about the mental health of the infected and/or people who are forced to stay in quarantine, as well as groups at risk for mental health problems. It is simply incomplete and too short. Please pay more attention towards the different periods during this pandemic.

  3. Please be much more critical on studies examining effects of the pandemic (very often using convenience samples and cross sectional studies without reference data prohibiting any valid conclusion about the effects of this pandemic on mental health), and include the recent meta-analysis of prospective studies of Robinson et al. 2021 (doi: 10.1016/j.jad.2021.09.098).

  4. Clarify which IRB was involved (not only the code of 201…..).

  5. Please explain how potentially respondents were contacted to ask to participate in your study. How were the questions administered (written, online, verbal?).  When were the questions administered (during quarantine, afterwards and how many weeks after the quarantine). Were other family members infected, in hospital because of infection, deceased following infection, etc.

  6. No information is provided about the non-response and results of the non-response analyses.

  7. Cronbachs alpha’s of the DASS-21 scales of the study sample are missing.

  8. Explain how a history of mental illness was assessed.

  9. Explain and clarify which “independent variables” were examined (and introduce/explain alll in the introduction).

  10. You entered the variables in the multivariate analyses that were significant in the univariate analyses on p <.025 level. I don’t understand this strategy. It is more informative to include all predictors in the multivariate analyses (and thus you can skip the univariate analyses).

  11. Show the prevalence of anxiety, depression and stress of all predictors in the table, and clarify which cut-off’s were used in the logistic regression analyses.

  12. The text suggest that you only examined age, gender, marital status, having a child, and income, besides administering the DASS-21. Is this correct? If not, why did you not include these other variables?

  13. Please improve your tables and present all relevant info, including explained variance, statistics of all include variables.

  14. As the reviewers noted, the discussion is not a discussion (for example a limitation section and comparisons with the results of other studies on infected/quarantined are completely absent). I would like to advise you to read other COVID-19 papers published in PLOS ONE on the mental health of patients/general population, that can be used as examples.

Please submit your revised manuscript by Dec 04 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Peter G. van der Velden, Ph.D.

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: No

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is an interesting study but it needs mayor revision before it can be considered again.

Authors should explain that they assessed non-hospitalized COVID.19 patients during the 14 days of quareenten. It is not clear. more data of COVID.19 fatures is needed. time from diagnosis is needeed. maybe anxiety and depression is not the same day one than 10 days after reclusing at home.

Differentiation between anciety and depresison in general population, hospitalized COVID-19 patients and long COVID patients is needed. Authors have assess moddo disorders in a manner that it is not commonly investigated in the literature, which increases the relevance of the paper, but more justification and discussion is needed.

What happened with these patients about 14 days? was any follow-up of them?

The role of gender needs extensive discussion since there is available data on the liteature for that

In conclusion, the paper needs xtensive inclusion of more data and extensive work before it can be reconsidered again.

Reviewer #2: Summary

The authors have attempted to assess the severity and prevalence of anxiety, depression, and stress and to identify risk factors in an adult cohort of participants with non-severe COVID-19 in the East Java province in Indonesia. They observed that depression was prevalent in 3.6% of the participants, anxiety in 14.3%, and stress in 7.9%. Furthermore, female gender was associated with a higher risk of anxiety and stress, and higher depression, anxiety, stress and total score. Based on these results, the authors conclude that depression, anxiety, and stress was prevalent in 3.6%, 14.3%, and 7.9%, that women are at higher risk and that women with confirmed COVID-19 should therefore be regularly evaluated.

Although this is an interesting study, a lot of work should be done prior to this work being ready to be published. My suggestions are described below:

General recommendations

- In my opinion, the level of English used could and should be better. There are quite many grammatical errors, suboptimal choices of verbs etc. Consider asking a native speaking colleague to copy-edit the manuscript.

- Including the outcomes of the univariate regression models does not fulfill the criteria of making all data underlying the findings described fully available; please add a dataset containing the raw data to fulfill this criterion.

Specific recommendations

Title

- I think “risk factor” should be “risk factors”, even though only one risk factor was identified.

Abstract

- I am missing the importance of your work/knowledge gap your research is filling in in your abstract

- “Study population was non-severe…” (line 31); I think “comprised” or “consisted of” would be a better verb

- “that was” (lines 31) should be “which were”

- “Collected data …. version 25.0” (lines 33-34) should be omitted from the abstract.

- “There were … in this study” (lines 34-35); Out of how many patients were those 608 included, in other words what was the inclusion/response rate.

- “From 608 respondents …” (line 35); in the phrase before it was already mentioned that there were 608 participants. I would suggest changing this to “Of these… “

- As you only used a screening instrument to detect psychological symptoms, I would suggest weaken the statements regarding having depression, anxiety, or stress. I think “reported” would be a better choice of verb.

- I would suggest adding the association between the severity of psychological symptoms (i.e., the scores) and female gender to your abstract.

- I don’t think the conclusion drawn can be extrapolated from the data presented. Although you demonstrate that female sex is a risk factor for psychological symptomatology, this does not mean that males doesn’t report any psychological symptoms (I imagine, as this comparison is not ready made in the manuscript).

Introduction

- I think in general the introduction is lacking important references.

- Lines 44 to 50 are not relevant, as everybody already knows about the COVID-19 pandemic. Try to be more creative when writing your introduction.

- I think much more literature regarding recent findings about psychological distress during COVID-19 should be added and described. The introduction in its present form lacks a description of why this research is important and what are the knowledge gaps. Why would you think that patients have psychological distress during COVID-19/a SARS-CoV-2 infection? What is already known? What isn’t known? What is your research going to add to the literature. I think “However, there is no study conducted that evaluates the mental health conditions among confirmed COVID-19 patients in Indonesia to this date” is not enough justification for your research.

- Overall, I think the introduction is to general, especially the first paragraph, and lacks a clear description of already published literature concerning this subject.

Methods

- “Study population was” (line 65): This is not correct English. Also, this sentence is too long, I would split it up in more sentences for clarity.

- “Inclusion criteria was … in this study” (lines 69-70): There are various grammatical errors in this sentence, please rephrase.

- “relevant institutional reviewer board” (lines 71-72): Please include the name of the institutional review board.

- I was expecting a paper describing the validity of the used screening questionnaire for reference 8. This reference however does not study this matter, but only uses the same instrument. Please provide a reference that is indeed studying the validity of the instrument. Are there any other references about the development of the DASS-21?

- Which sociodemographic characteristics were asked for? In the results, only age, sex, marital status, having a child and incomes are listed, are those also the only demographic variables that were gathered?

- I think the listing of the cut-off values is quite chaotic. Maybe it is an idea to add a table (in the main manuscript or additional files) which gives a clear oversight of the cut-of values.

- It is totally unclear to me why only the abovementioned variables were used to identify risk factors for the development of anxiety, depression, or stress. Was this based on existing literature? Please describe this in much more detail in the manuscript.

- Were all patients included in just one month (September 2020)? Otherwise, specify the start and ending date of the study.

- When and how were patients recruited and included?

- Why were patients with a history of mental illness excluded? How was this determined?

- You only describe that you use logistic and linear regression analysis, but it is not clear for which they are used. This should be made more clear.

Results

- I am missing the total number of patients who were eligible, from which the 608 participants were included. It might be an idea to include a flow diagram to show this.

- I am missing a table depicting the descriptives of the main outcomes, which are the prevalence and severity (i.e., sum scores) of the domains of the DISS-21. It is now only described in the text. In this way, you can omit the text regarding the distribution among mild, moderate or severe psychological distress, and just refer to the table.

- It might be an interesting idea to group the cohort based on their outcomes (i.e., patients who reported psychological stress vs. patients who did not), and compare these groups.

- I think the first paragraph could be written in a less point-to-point manner.

- Table S1: Where does ‘COR’ stand for? Abbreviations should be explaned for each table (not this is only done for table S2 and Table 3.

- Table 2: I do not understand why ‘having at least one child’ is not added to the multiple logistic regression model, as these variables had a p-value <0.25 in the univariate logistic regression model.

- Tabel 2: Why does this table include ‘depression’ as no multiple regression analysis was conducted for this outcome?

- Table 3: I would suggest adding all variables, including their Beta, SE, etc. for all components which were added to the model. In that way, you don’t have to describe everywhere for which other variables were adjusted.

- Table 3: I do not understand why the multiple linear model for anxiety was adjusted for having a child and marital status, when marital status did not have a p-value below 0.25 in the univariate analysis.

- Overall, I think the results section can be written in a more clear and organized manner.

Discussion

I think the discussion needs a lot of work; in its present form it is 1) way too shallow and 2) the authors have failed to discuss any truly important topics.

Try to rewrite the discussion using the following paragraphs:

First paragraph: Short repetition of the main results.

Second and further paragraphs: Discussing observed main results with recent literature.

Last paragraph: Limitations

In its present form, the authors already start discussing their results in the first paragraph by mentioning another study in COVID-19 confirmed cases. I think, if that is a point of discussion, the authors should elaborate more on these results, and also compare with, for instance, papers which report the prevalence of psychological distress after COVID-19. Other literature concerning this matter is hardly referred to.

Also, the only true discussion the authors describe is the fact the women are more prone to psychiatric sequelae after COVID-19. That is, in my opinion, not new or surprising at all and definitely not enough on its own for a discussion. The fact that the whole manuscript only counts 17 references, of which 5 are not even scientific papers, underscores my point.

Conclusion

The conclusion in its present form is just a repetition of the main results of this study and not so much of an conclusion, except that the psychological well-being of COVID-19 positive women should be evaluated regularly. In my opinion, the conclusion section should never contain number, as the results section is the only place to report these. As such, I think the conclusion should be rewritten.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Jul 7;17(7):e0270966. doi: 10.1371/journal.pone.0270966.r002

Author response to Decision Letter 0


23 Feb 2022

Dear editor and reviewers,

Thank you for the comments and suggestions for this manuscript. We have uploaded the point-to-point response in the submission files.

Attachment

Submitted filename: Response to reviewer.docx

Decision Letter 1

Peter G van der Velden

4 Apr 2022

PONE-D-21-21429R1Prevalence of and risk factors for depression, anxiety, and stress in confirmed non-severe COVID-19 patients in East Java province, IndonesiaPLOS ONE

Dear Dr. Salamah,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. I agree with the comments of the reviewers (see below) and therefore will not repeat them here.

Please submit your revised manuscript by May 19 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Peter G. van der Velden, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Authors have answered most comment. The pper is much improved. Nevertheless, the introduction is still slightly confusing. Authorsd talk about mental health, but they do not clarify until the end of the introduction that they are talking of non infected patients. Authors should update current data on mental health in infected COVID-19 patients, both hospitalized and non-hospitalized. This should be clear in the introduction and use this information in the discussion

In addition, the title should use non-hospitalized patients instead of non-severe.

Reviewer #2: Dear authors,

Thank you for the opportunity to review your revised manuscript. I would like to congratulate you on your work as the revised manuscript has improved tremendously.

I however still think there should be made some minor revisions prior to the manuscript being ready for publication.

Abstract:

The authors did a good job improving their abstract and the use of the English language within the abstract. There are some small improvements to make:

1) Could you add the coefficients of your regression models when mentioning the risk factors, as only mentioning those won’t help the reader understand the correlation/association.

2) I would suggest adding some baseline demographics of the cohort, such as age, gender etc. to the abstract.

2) I would rephrase or even omit your recommendation. I think it is a nice conclusion that psychological distress was not that apparent in non-severe COVID-19 patients, but I do not believe that there should indeed be paid more attention to the psychological distress of these patients as psychological distress is that scarce. It seems even comparable or just a little bit higher (anxiety) than the expected prevalence of those disorders in non-COVID-19 times. Although I understand the authors tendency to give a recommendation, this recommendation is too general in my opinion, and I’m doubting whether the government is the one to pay attention, rather than employers (as HCW were more likely to report depression for instance).

Although it is the authors choice, I would prefer a structured abstract over a narrative abstract, especially considering the design of your study.

Introduction:

- Overall, I think the introduction improved a lot compared to the previous version. There are however some minor improvements to be made:

- I would pay some more attention to the first paragraph. The coronavirus disease 2019 was not identified as a global pandemic, but the spread of the virus causing this disease was classified as a pandemic. The disease does not infect people, the virus does. “Various preventive public health measures have been implemented”; as most of these measures have already been omitted, I would say ‘were implemented’ (have been implemented implies that it is currently still the case).

- There are still some grammatical errors in the introduction, especially in the use of verbs.

- I would suggest bundling the reasons for conducting your research (the lack of data from LMIC, differs across time periods etc.) to one paragraph. It helps you being more concise, which would improve the introduction.

Methods:

- I would like to congratulate the authors on the revisions made in the Methods, it has improved considerably. There are some minor changes to made:

- “… and information about informed consent was given before the consent form was signed.” I think this should be information about the study (I hope so at least)

- Thank you for summarizing the cut-offs of the questionnaire in a table, this is much more convenient for the reader and much less chaotic than the previous version. Good job.

- Although all possible risk factors are mentioned in the methods now, it is not really clear to me why you choose those variables. Was is based on literature concerning risk factors for psychological distress or were they chosen as they were easily gathered? Please explain in the methods. (in other words, why would you think that risk factors would be among those gathered variables?)

Results:

- Thank you for adding the flow diagram and the total number of patients assessed.

- “For regression analysis, all sociodemographic variables from Table 1 were included, except educational background and family income, as these variables had a higher percentage of missing data”; Could you also describe in the Methods section that variables that had a certain percentage of missing data were excluded from the data analysis.

Discussion:

Of all sections, the discussion section has improved the most. I think the discussion in its present form is very complete and most important topics are covered. I have no comments to improve the discussion.

Conclusion

The present conclusion is much better than the previous one. Only comment is that I would rephrase your recommendation, as also stated in the abstract.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Johan H. Vlake

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Jul 7;17(7):e0270966. doi: 10.1371/journal.pone.0270966.r004

Author response to Decision Letter 1


21 Apr 2022

Dear reviewers,

Thank you for the comments and suggestions for this manuscript. We have uploaded the point-to-point response in the online submission system.

Attachment

Submitted filename: Response to reviewer.docx

Decision Letter 2

Peter G van der Velden

22 Jun 2022

Prevalence of and risk factors for depression, anxiety, and stress in non-hospitalized asymptomatic and mild COVID-19 patients in East Java province, Indonesia

PONE-D-21-21429R2

Dear Dr. Salamah,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards and congratulations with your paper,

Peter G. van der Velden, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Authors have addressed all comments properly from this reviewer and the other reviewer. The paper can be now accepted

Reviewer #2: I would like to congratulate the authors on their revision, which considerably improved the manuscript.

I believe that it is now ready for publication.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Johan Hendrik Vlake

**********

Acceptance letter

Peter G van der Velden

27 Jun 2022

PONE-D-21-21429R2

Prevalence of and risk factors for depression, anxiety, and stress in non-hospitalized asymptomatic and mild COVID-19 patients in East Java province, Indonesia

Dear Dr. Salamah:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. dr. Peter G. van der Velden

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Raw data

    (SAV)

    Attachment

    Submitted filename: Response to reviewer.docx

    Attachment

    Submitted filename: Response to reviewer.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES